The randomized, controlled OASIS-2 trial comparing omadacycline and linezolid for the treatment of adult patients with an acute bacterial skin and skin structure infection (ABSSSI) known or suspected to be due to a Gram-positive pathogen enrolled 735 patients, with 368 and 367 in each group, respectively.1 Patients completed the 36-Item Short Form Health Survey, version 2 (SF-36v2), a validated questionnaire on physical and mental health.
Results of the SF-36v2 were analyzed in accordance with established norm-based standards for the survey for the intention-to-treat population.2 Patients who received omadacycline experienced a 3.25-point mean improvement in overall physical health (P <.001 compared with baseline) and reported significant improvements across all but one component parameter of overall physical and mental health, including physical functioning, bodily pain, role physical, vitality, role emotional, mental health, and social functioning. In contrast, although overall physical health improved for patients who received linezolid, the improvement in vitality, role emotional, mental health, and general health was not significant. Although omadacycline achieved a greater improvement from baseline than linezolid across all quality-of-life domains analyzed, the difference in scores was not statistically significant.
Omadacycline provides significant improvement in the physical component of quality of life over baseline for adult patients with ABSSSI known or suspected to be due to a Gram-positive pathogen, and demonstrates a numerically greater improvement than linezolid.
References
- Tzanis E, et al. IDWeek 2018. Abstract 1356.
- Ware JE Jr. SF-36 health survey update. Spine (Phila Pa 1976). 2000;25:3130-3139.